The coagulation system as a target for experimental therapy of human gliomas

Expert Opinion on Therapeutic Targets
J T Loynes, L R Zacharski

Abstract

The purpose of this paper is to review the rationale for the development of coagulation-reactive drugs for the experimental therapy of gliomas. Numerous reactants familiar to students of blood coagulation have been shown to contribute to neoplastic proliferation, invasion and metastasis. Recently, considerable progress has been made in demonstrating the ability of drugs capable of inhibiting these reactants to alter cancer progression. Biological features of gliomas within the realm of blood coagulation suggest that clinical trials of such drugs warrant consideration. This approach offers the prospect of a novel treatment for this devastating tumour type that does not share the toxicities of conventional cancer therapies.

References

Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·B M MuellerW Ruf
Feb 1, 1980·Neurosurgery·J B Valladares, J Hankinson
Jan 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·J D PalmerF Iannotti
Dec 30, 1994·Biochemical and Biophysical Research Communications·K D JonesR E Law
Apr 1, 1994·Mayo Clinic Proceedings·J F QuevedoJ R O'Fallon
Jun 5, 1998·JAMA : the Journal of the American Medical Association·R S Rosenson, C C Tangney
Aug 13, 1998·Seminars in Thrombosis and Hemostasis·K NakagawaM Nakagawa
Apr 28, 1999·Journal of Neuropathology and Experimental Neurology·M NakadaH Sato
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·K AbeF R Rickles
Aug 6, 1999·Journal of Thrombosis and Thrombolysis·A T ChanS Z Goldhaber
Mar 22, 2000·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·J W FentonF A Ofosu
Aug 10, 2000·Journal of the American College of Cardiology·D FerroF Violi
May 25, 2001·International Journal of Hematology·D L Ornstein, L R Zacharski
Mar 9, 2002·Seminars in Thrombosis and Hemostasis·Deborah L OrnsteinLeo R Zacharski
Mar 9, 2002·Seminars in Thrombosis and Hemostasis·Dongfang LiuRam Sasisekharan
Jul 24, 2002·Clinical Biochemistry·Ming GuanYuan Lu
Aug 13, 2002·Current Opinion in Pulmonary Medicine·Leo R Zacharski, James T Loynes
Sep 18, 2002·Cancer Treatment Reviews·Paul Thodiyil, Ajay K Kakkar
Oct 17, 2002·Journal of Neurology·Friederike SchmidtMichael Weller

❮ Previous
Next ❯

Citations

Feb 8, 2006·Journal of Thrombosis and Haemostasis : JTH·C RossiA Poggi
Nov 13, 2012·Journal of Neurosurgery. Pediatrics·Koshiro Nishikuni, Guilherme Carvalhal Ribas
Feb 4, 2010·Neurosurgical Focus·Guilherme Carvalhal Ribas
Aug 13, 2014·World Journal of Clinical Oncology·Nobuhiro KanajiTakuya Matsunaga
Oct 9, 2021·Seminars in Thrombosis and Hemostasis·Anne Winther-LarsenAnne-Mette Hvas

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.